Occurrence of recurrent venous thromboembolic and major bleeding complications in 181 patients with extensive, moderately extensive, or less extensive cancer and 661 venous thrombosis patients without cancer
| . | Extent of cancer . | ||||
|---|---|---|---|---|---|
| No cancer, n = 661 . | All cancer, n = 181 . | Extensive, n = 67 (37.0%) . | Moderately extensive, n = 40 (22.1%) . | Less extensive, n = 74 (40.9%) . | |
| Overall duration of anticoagulation (patient-y) | 270.1 | 111.3 | 25.1 | 26.8 | 59.3 |
| Recurrent VTE/100 patient-y | 12.8 | 30.0 | 54.1 | 44.1 | 14.5 |
| Hazard ratio (95% CI)3-150 | 3.2 (1.9-5.4) | 4.6 (2.3-9.0) | 5.3 (2.5-10.9) | 1.9 (0.8-4.2) | |
| Major bleeding/100 patient-y | 8.6 | 15.7 | 42.8 | 19.1 | 3.4 |
| Hazard ratio (95% CI)3-150 | 2.2 (1.2-4.1) | 4.8 (2.3-10.1) | 2.5 (0.9-6.7) | 0.5 (0.1-2.1) | |
| . | Extent of cancer . | ||||
|---|---|---|---|---|---|
| No cancer, n = 661 . | All cancer, n = 181 . | Extensive, n = 67 (37.0%) . | Moderately extensive, n = 40 (22.1%) . | Less extensive, n = 74 (40.9%) . | |
| Overall duration of anticoagulation (patient-y) | 270.1 | 111.3 | 25.1 | 26.8 | 59.3 |
| Recurrent VTE/100 patient-y | 12.8 | 30.0 | 54.1 | 44.1 | 14.5 |
| Hazard ratio (95% CI)3-150 | 3.2 (1.9-5.4) | 4.6 (2.3-9.0) | 5.3 (2.5-10.9) | 1.9 (0.8-4.2) | |
| Major bleeding/100 patient-y | 8.6 | 15.7 | 42.8 | 19.1 | 3.4 |
| Hazard ratio (95% CI)3-150 | 2.2 (1.2-4.1) | 4.8 (2.3-10.1) | 2.5 (0.9-6.7) | 0.5 (0.1-2.1) | |
As compared with patients without cancer.